17 Nov 08 Case Of Patient "Cured" Of HIV Baffles Doctors
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been “cured” by a bone marrow transplant given to treat his acute myeloid leukemia.
(more…)
Tags: Acute Myeloid Leukemia, American Patient, Baffles, Bone Marrow, Doctors, Hiv, Hiv Infection, Leukemia, Living In Berlin
17 Nov 08 Documentary Examining Deadly Blood Disorders And Lifesaving Research To Premiere On Discovery Health
Peabody-Award-winning filmmaker, Joseph Lovett, in conjunction with the American Society of Hematology (ASH) presents BLOOD DETECTIVES, an hour-long documentary airing on Discovery Health on December 19, 2008, at 7:00 p.m. ET/PT and again at 12:00 a.m. ET/PT. BLOOD DETECTIVES focuses on the medical mysteries and lifesaving work of highly specialized doctors, hematologists, as they race against time to unravel medical mysteries and save lives, from leukemia to blood clots and more.
(more…)
Tags: Ash, Blood Clots, Blood Disorders, Conjunction, Deadly Blood, Detectives, Discovery Health, Doctors, Documentary, Filmmaker, Hematology, Joseph Lovett, Leukemia, Medical Mysteries, Peabody Award, Premiere, Presents, Race Against Time
17 Nov 08 INNO-406 Demonstrates Positive Clinical Responses In Phase 1 Trial In Patients With Chronic Myeloid Leukemia
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx’s potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML).
(more…)
Tags: Abl, Biopharmaceutical Company, Chronic Leukemia, Chronic Myeloid Leukemia, Clinical Responses, Clinical Trial, Cml, Commercialization, Kinase Inhibitor, Leukemia, Lyn, Nasdaq, Phase 1, Today Announced That
11 Nov 08 Effectiveness Of Bone Marrow Transplant In Suppressing HIV Creates Hope For Gene-Therapy Strategies In Treating Virus, Wall Street Journal
The Wall Street Journal on Friday examined the case of an HIV-positive person who underwent a bone marrow transplant to treat leukemia and who has had undetectable HIV viral loads for almost two years. The procedure — performed by German hematologist Gero Hutter of Berlin’s
(more…)
Tags: Berlin, Bone Marrow Transplant, Gene Therapy Strategies, Gero, Hematologist, Hiv, Hiv Positive, Hutter, Leukemia, Undetectable Hiv, Viral Loads, Virus Wall, Wall Street, Wall Street Journal
11 Nov 08 Genmab A/S: Ofatumumab Pivotal CLL Data To Be Presented At ASH
Genmab A/S (OMX: GEN) announced that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of Hematology Annual Meeting and Exposition (ASH) December 6-9, 2008. Updated interim efficacy data from the pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic leukemia (CLL) patients with an unmet medical need will be presented in an oral session.
(more…)
Tags: Annual Meeting, Ash, Cd20, Chronic Leukemia, Chronic Lymphocytic Leukemia, Efficacy Data, Exposition, Hematology, Humax, Interim, Leukemia, Ofatumumab, Omx, Oral Session, Pivotal Study, Presentation, Study Groups, Unmet Medical Need
09 Nov 08 Researchers Find Predictive Tests And Early Treatment Delay Progression Of Blood Cell Cancer
Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapy in patients with early-stage, but high-risk, chronic lymphoid leukemia (CLL). Their study, published Oct.
(more…)
Tags: Biomarkers, Blood Cancer, Blood Cell, Cancer Clinic, Cell Cancer, Chemotherapy, Chronic Lymphoid Leukemia, Conventional Chemotherapy, Delay Progression, Leukemia, Mayo Clinic Researchers, Personalized Care, Predictive Tests
09 Nov 08 CIGNA To Promote The Leukemia & Lymphoma Society’s Co-Pay Assistance Program, USA
CIGNA Pharmacy Management (CIGNA) and the Leukemia & Lymphoma Society (LLS) are joining forces to promote LLS’s efforts to help blood cancer patients cover the costs of prescription co-pays and health insurance premiums. The costs of cancer are significant. According to the National Cancer Institute, direct medical costs for cancer care in 2004 totaled more than $72 billion.
(more…)
Tags: Amp, Assistance Program, Blood Cancer, Cancer Care, Cancer Patients, Cigna, Health Insurance, Health Insurance Premiums, Insurance, Leukemia, Leukemia Lymphoma, Leukemia Society, Lls, Lymphoma, Lymphoma Society, Medical Costs, National Cancer Institute, Pharmacy Management, Program Management, Usa Pharmacy
09 Nov 08 CIGNA To Promote The Leukemia & Lymphoma Society’s Co-Pay Assistance Program, USA
CIGNA Pharmacy Management (CIGNA) and the Leukemia & Lymphoma Society (LLS) are joining forces to promote LLS’s efforts to help blood cancer patients cover the costs of prescription co-pays and health insurance premiums. The costs of cancer are significant. According to the National Cancer Institute, direct medical costs for cancer care in 2004 totaled more than $72 billion.
(more…)
Tags: Amp, Assistance Program, Blood Cancer, Cancer Care, Cancer Patients, Cigna, Health Insurance, Health Insurance Premiums, Insurance, Leukemia, Leukemia Lymphoma, Leukemia Society, Lls, Lymphoma, Lymphoma Society, Medical Costs, National Cancer Institute, Pharmacy Management, Program Management, Usa Pharmacy
09 Nov 08 Researchers Find Predictive Tests And Early Treatment Delay Progression Of Blood Cell Cancer
Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapy in patients with early-stage, but high-risk, chronic lymphoid leukemia (CLL). Their study, published Oct.
(more…)
Tags: Biomarkers, Blood Cancer, Blood Cell, Cancer Clinic, Cell Cancer, Chemotherapy, Chronic Lymphoid Leukemia, Conventional Chemotherapy, Delay Progression, Leukemia, Mayo Clinic Researchers, Personalized Care, Predictive Tests
07 Nov 08 First-Ever Mapping of Cancer Patient's Genome (HealthDay)
HealthDay - WEDNESDAY, Nov. 5 (HealthDay News) — In a genetics first,
researchers report that they have decoded the complete DNA sequence of a
person with acute myelogenous leukemia.
(more…)
Tags: Acute Myelogenous Leukemia, Cancer Patient, Dna Sequence, Genetics, Genome, Healthday, Leukemia, Mapping, Nov 5
06 Nov 08 Tackling Hard-to-treat Childhood Cancer By Targeting Epigenetic Changes
A very difficult-to-treat child leukemia may benefit from the discovery of a small but potent epigenetic change that launches the cancer - but could potentially be reversed relatively easily, preventing cancer-promoting genes from being turned on. The study, led by researchers at Children’s Hospital Boston and the
(more…)
Tags: Cancer Genes, Child Leukemia, Childhood Cancer, Discovery, Epigenetic Changes, Hospital Boston, Led, Leukemia, S Hospital
06 Nov 08 Washington University Scientists First To Sequence Genome Of Cancer Patient
For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots. A large research team at the Genome Sequencing Center and the Siteman Cancer Center at Washington University School of Medicine in St. Louis sequenced the genome of the patient - a woman in her 50s who ultimately died of her disease and the genome of her leukemia cells, to identify genetic changes unique to her cancer.
(more…)
Tags: 50s, Acute Leukemia, Acute Myelogenous Leukemia, Cancer Patient, Dna, Genetic Changes, Genetic Roots, Genome Sequencing Center, Leukemia, Leukemia Cells, Medicine, School Of Medicine, Sequence Genome, Siteman Cancer Center, Time Scientists, University Scientists, Washington University School Of Medicine, Woman
06 Nov 08 First-Ever Mapping of Cancer Patient's Genome (HealthDay)
HealthDay - WEDNESDAY, Nov. 5 (HealthDay News) — In a genetics first,
researchers report that they have decoded the complete DNA sequence of a
person with acute myelogenous leukemia.
(more…)
Tags: Acute Myelogenous Leukemia, Cancer Patient, Dna Sequence, Genetics, Genome, Healthday, Leukemia, Mapping, Nov 5
05 Nov 08 Blocking enzyme may help childhood leukemia: study (Reuters)
Reuters - A simple enzyme may hold the key to tackling a hard-to-treat type of leukemia in babies, U.S. researchers said on Monday.
(more…)
Tags: Babies, Childhood Leukemia, Enzyme, Leukemia, Leukemia Study, Reuters
05 Nov 08 Blocking A Histone-Modifying Enzyme May Calm Down Gene Expression Driving Some Leukemias
A very difficult-to-treat child leukemia may benefit from the discovery of a small but potent epigenetic change that launches the cancer - but could potentially be reversed relatively easily, preventing cancer-promoting genes from being turned on. The study, led by researchers at Children’s Hospital Boston and the Dana-Farber Cancer Institute, is the cover article in the November 4 issue of Cancer Cell.
(more…)
Tags: Cancer Cell, Child Leukemia, Cover Article, Dana Farber Cancer, Dana Farber Cancer Institute, Discovery, Enzyme, Farber Cancer Institute, Gene Expression, Genes, Histone, Hospital Boston, Leukemia, Leukemias, S Hospital
17 Oct 08 Chronic Myeloid Leukemia - Data From EUTOS For CML Demonstrate Need For Improved Management And Dose Optimization Across Europe
One-year data from the European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML), presented here today, provide a clear rationale for the initiative’s program of close disease management and therapeutic monitoring.
(more…)
Tags: Chronic Leukemia, Chronic Myeloid Leukemia, Cml, Disease Management, Dose Optimization, Europe, Improved Management, Initiative, Leukemia, Outcome Study, Rationale
17 Oct 08 Chronic Myeloid Leukemia - Data From EUTOS For CML Demonstrate Need For Improved Management And Dose Optimization Across Europe
One-year data from the European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML), presented here today, provide a clear rationale for the initiative’s program of close disease management and therapeutic monitoring.
(more…)
Tags: Chronic Leukemia, Chronic Myeloid Leukemia, Cml, Disease Management, Dose Optimization, Europe, Improved Management, Initiative, Leukemia, Outcome Study, Rationale
12 Oct 08 On The Trail Of A Targeted Therapy For Blood Cancers: Exploring Protein Critical To Blood Cell Development
Investigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults. Their findings may one day help in the development of targeted therapies for leukemia, multiple myeloma and other cancers of the blood. The researchers, led by Kristin T. Chun, Ph.D.
(more…)
Tags: Adults, Blood Cancers, Blood Cell, Blood Protein, Blood Proteins, Chemotherapy, Effects Of Chemotherapy, Indiana University School, Indiana University School Of Medicine, Investigators, Led, Leukemia, Medicine, Multiple Myeloma, Pediatric Research, School Of Medicine, Toxic Effects, Wells Center
12 Oct 08 Cyclacel Announces Completion Of Enrollment In Phase 2 Trial Of Sapacitabine In Elderly AML
lCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the completion of enrollment as per protocol in the Phase 2 clinical trial of sapacitabine, the Company’s oral nucleoside analogue, in elderly patients with acute myeloid leukemia (AML). Interim results from this trial are expected to be available by the end of 2008 and final results during the second half of 2009.
(more…)
Tags: Acute Leukemia, Acute Myeloid Leukemia, Clinical Trial, Cycc, Elderly Patients, Interim Results, Leukemia, Leukemia Aml, Nasdaq, Nucleoside Analogue, Oral, Pharmaceuticals Inc, Phase 2, Protocol, Second Half
12 Oct 08 On The Trail Of A Targeted Therapy For Blood Cancers: Exploring Protein Critical To Blood Cell Development
Investigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults. Their findings may one day help in the development of targeted therapies for leukemia, multiple myeloma and other cancers of the blood. The researchers, led by Kristin T. Chun, Ph.D.
(more…)
Tags: Adults, Blood Cancers, Blood Cell, Blood Protein, Blood Proteins, Chemotherapy, Effects Of Chemotherapy, Indiana University School, Indiana University School Of Medicine, Investigators, Led, Leukemia, Medicine, Multiple Myeloma, Pediatric Research, School Of Medicine, Toxic Effects, Wells Center
